Benjamin Wolozin, MD, PhD
Professor of Pharmacology and Neurology at Boston University School of Medicine
Benjamin Wolozin, MD, PhD, is a professor of Pharmacology and Neurology at Boston University School of Medicine, where he is also senior faculty advisor for the MD, PhD Program.
Dr. Wolozin completed his undergraduate education at Wesleyan University in Middletown, Connecticut. He earned his MD and PhD degrees from Albert Einstein College of Medicine in 1988. His postdoctoral fellowships were spent at Mt. Sinai Medical Center (1988-89) and the National Institute of Mental Health (1989 – 96). He joined Loyola University Medical Center in 1996 and moved to Boston University in 2004.
Dr. Wolozin’s Alzheimer’s research focuses on the role of cholesterol in Alzheimer’s disease and investigating mechanism by which statins might impact on the pathophysiology of the disease. His research on Parkinson's disease focuses on identifying the mechanism of action of genes associated with familial PD, and how these genes interact with aging and environmental stress.
Dr. Wolozin has received numerous awards for his research, including the Donald B. Lindsley Prize, Society for Neuroscience, the A. E. Bennett Award from the Society for Biological Psychiatry, the Merit Award from Alzforum, the Graduate Faculty of the Year Award from Loyola University Medical Center and the Memory Ride Award from the Massachusetts Chapter of the Alzhiemer Association. He serves on editorial boards for the Journal of Biological Chemistry, Current Alzheimer’s Research and Neurodegenerative Diseases, and is a standing member of the NIH CDIN study section. He has published over 100 papers or book chapters, and been awarded four patents in the field of Parkinson’s disease and Alzheimer’s disease.
- SIRT1 Activators as Therapy for Parkinson's Disease (2008)
- Identification of therapeutics that protect against toxins and genes implicated in Parkinsonís disease via the Forkhead-mediated transcription pathway (2006)
- New Small Molecule Inhibiting Agents of Alpha-Synuclein & Lewy Body Formation as Disease-Modifying Treatments for Parkinson's Disease (2005)